News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘TargetedTherapy’ clear

  • Dana-Farber researchers have found that a combination of two already-in-use drugs may have an effect on stopping the growth of the most common genetic subtype of lung cancer setting the stage for clinical trials.

Tags: LungCancer, TargetedTherapy

  • Scientists have identified a mutated gene that causes a type of benign brain tumor that can have devastating lifelong effects. It may be possible to attack the tumors with targeted drugs already in use for other tumors.

Tags: TargetedTherapy, BrainTumors

  • In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment.

Tags: chemotherapy, BreastCancer, TargetedTherapy

  • The Joint Center for Cancer Precision Medicine, a collaborative initiative among Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard, has been established to create “precision medicine treatment pathways” for patients with advanced cancers and to speed the development of personalized therapies.

Tags: Genomics, Partnerships, TargetedTherapy, Genetics

  • A targeted drug that reduces blood flow to tumors prolonged the survival of patients with advanced stomach cancer after standard treatments failed, according to results of large multicenter clinical trial led by scientists at Dana-Farber Cancer Institute.

Tags: chemotherapy, TargetedTherapy

  • Scientists have catalogued more than 5,000 tumor DNA profiles in a database of genetic abnormalities in cancer, a resource aimed at tailoring highly specific drugs to the particular genetic mutations and other abnormalities that drive a patient's cancer.

Tags: Genomics, TargetedTherapy, Genetics

  • Dana-Farber researchers reported that patients with non-small cell lung cancer (NSCLC) whose tumor cells harbored an abnormal ALK gene responded better to targeted therapy than traditional chemotherapy.

Tags: LungCancer, TargetedTherapy

  • Dana-Farber scientists found that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control the deadly cancer.

Tags: PancreaticCancer, TargetedTherapy

  • A study by scientists at Dana-Farber Cancer Institute, the Broad Institute, and other research centers, may offer clues to why rates of esophageal adenocarcinomas (EACs) have risen so sharply. The findings, in Nature Genetics, point to an array of abnormal genes and proteins that may be lynchpins of EAC cell growth and therefore serve as targets for new therapies.

Tags: Genomics, TargetedTherapy

  • Scientists from Dana-Farber and the Broad Institute have identified two DNA mutations that appear to drive about 15 percent of meningiomas, a finding that could lead to the first effective drug treatments for the brain tumor.

Tags: TargetedTherapy, BrainTumors

Showing 11-20 of 40 items